Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials
- 12 May 2025
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (7) , 3249-3264
Abstract
Introduction Therapeutic options for patients with advanced non-small cell lung cancer (NSCLC) after progression on immune checkpoint inhibitors (ICIs) remain a significant challenge. This analysis compared outcomes of anlotinib plus docetaxel versus docetaxel alone in this population using the pooled data from two prospective randomized trials (ALTER-L016; ALTER-L018). Methods Adult patients with EGFR/ALK/ROS1 wild-type advanced NSCLC progressing on first-line ICIs were eligible. Patients were randomly assigned to anlotinib plus docetaxel or docetaxel alone. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Results Seventy-one patients were included in this pooled analysis (L016, n = 39; L018, n = 32), of whom, 40 received anlotinib plus docetaxel and 31 received docetaxel. The median follow-up of all patients was 27.0 months. The median PFS was longer with anlotinib plus docetaxel than with docetaxel alone (5.4 months [95% CI 5.0–9.3] vs. 2.3 months [95% CI 1.4–2.9]; hazard ratio [HR], 0.34; 95% CI 0.18–0.63; P < 0.001). Both ORR (25.0% vs. 12.9%) and DCR (82.5% vs. 45.2%) were higher in the anlotinib plus docetaxel group than in the docetaxel group. Median OS was 16.2 months (95% CI 8.3–21.3) with anlotinib plus docetaxel versus 13.7 months (95% CI 4.6–22.3) with docetaxel (HR = 0.82; 95% CI 0.47–1.44; P = 0.488). Subsequent ICI therapy was associated with a longer OS. Grade 3 treatment-related adverse events occurred in 32.5% of patients receiving anlotinib plus docetaxel and 6.5% of patients receiving docetaxel. Conclusion Anlotinib plus docetaxel improved PFS but not OS versus docetaxel in patients with advanced NSCLC progressing on ICIs. Larger standardized phase 3 trials are needed to verify these findings. Trial Registration ALTER-L016 (ClinicalTrials.gov identifier, NCT03726736). ALTER-L018 (ClinicalTrials.gov identifier, NCT03624309).Keywords
Funding Information
- Beijing Xisike Clinical Oncology Research Foundation (Y-2019Genecast-024)
- Hunan Cancer Hospital Climb Plan (ZX2020005-5)
- The science and technology innovation Program of Hunan Province (2023SK4024, 2021SK51121)
- Hunan Lung Cancer Clinical Medical Research Center (2023SK4024)
- Hunan Provincial Natural Science Foundation of China (2021JJ30430)
This publication has 31 references indexed in Scilit:
- Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitor Therapy: Insights from VARGADO, A Prospective Study in Patients with Lung AdenocarcinomaFuture Oncology, 2019
- Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patientsThoracic Cancer, 2019
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- Anlotinib: First Global ApprovalDrugs, 2018
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challengesNature Reviews Clinical Oncology, 2018
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancerLung Cancer, 2017
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formationScience Translational Medicine, 2017
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCJournal of Thoracic Oncology, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017